- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, September 15, 2017
Coverage of our peer-reviewed research in the healthcare and mainstream press.
New research about overtreatment in US healthcare published in PLOS One cited a study from The American Journal of Managed Care® (AJMC®) as a reference. “Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors,” published in the June 2013 issue of AJMC®, found that overuse of these tests is common and can be linked to patient and clinician factors. The AJMC® newsroom recently featured an article covering the findings of the PLOS One study on unnecessary medical care.
An article from the AJMC® newsroom was highlighted in the National Pharmaceutical Council’s Wednesday e-newsletter. The story, “New Value-Based Insurance Plan Helps Consumers Who Use Healthcare the Most,” covered an innovative plan announced by Altarum that will use reference pricing to encourage consumers to seek high-value care. A. Mark Fendrick, MD, director of the University of Michigan Center for Value-Based Insurance Design and co-editor-in-chief of AJMC®, explained that the model could align consumer and provider incentives on quality and cost.
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
January 7th 2025Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More
